Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score
作者： Linda M Henricks , Carin ATC Lunenburg , Didier Meulendijks , Hans Gelderblom , Annemieke Cats
DOI: 10.2217/PGS.15.70
关键词:
摘要: … Consequently, there is a need for an individualized recommendation of dose adjustment of fluoropyrimidines, taking into account the specific genetic variants and their resulting …
core.ac.uk
futuremedicine.com
sci-hub.se 参考文章(56)
Daniel Marchalik, Andrew Lipsky, Dmitriy Petrov, Jeff D. Harvell, Sandy S. Milgraum, Dermatologic Presentations of Orthopedic Pathologies American Journal of Clinical Dermatology. ,vol. 13, pp. 293- 310 ,(2012) , 10.2165/11595880-000000000-00000
Andre Van Kuilenburg, Rutger Meinsma, Lida Zoetekouw, Albert Van Gennip, High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity Pharmacogenetics. ,vol. 12, pp. 555- 558 ,(2002) , 10.1097/00008571-200210000-00007
Tanja K. Froehlich, Ursula Amstutz, Stefan Aebi, Markus Joerger, Carlo R. Largiadèr, Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity International Journal of Cancer. ,vol. 136, pp. 730- 739 ,(2014) , 10.1002/IJC.29025
W Schwabe, D Behnke, P Häusler, A B Van Kuilenburg, K Höffken, A H Van Gennip, M Raida, Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5′-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)- related Toxicity Compared with Controls Clinical Cancer Research. ,vol. 7, pp. 2832- 2839 ,(2001)
L Zoetekouw, H R Waterham, D J Richel, A B van Kuilenburg, F Baas, J Haasjes, R Meinsma, A H van Gennip, E W Muller, Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clinical Cancer Research. ,vol. 7, pp. 1149- 1153 ,(2001)
E. Gamelin, M. Boisdron-Celle, V. Guérin-Meyer, R. Delva, A. Lortholary, F. Genevieve, F. Larra, N. Ifrah, J. Robert, Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage Journal of Clinical Oncology. ,vol. 17, pp. 1105- 1105 ,(1999) , 10.1200/JCO.1999.17.4.1105
Robert B. Diasio, Martin R. Johnson, Kangsheng Wang, Profound Dihydropyrimidine Dehydrogenase Deficiency Resulting from a Novel Compound Heterozygote Genotype Clinical Cancer Research. ,vol. 8, pp. 768- 774 ,(2002)
Josefa Salgado, Natalia Zabalegui, Carmen Gil, Ignacio Monreal, Javier Rodríguez, Jesús García-Foncillas, Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncology Reports. ,vol. 17, pp. 325- 328 ,(2007) , 10.3892/OR.17.2.325
Adam M. Lee, Qian Shi, Emily Pavey, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L. Berenberg, Richard M. Goldberg, Robert B. Diasio, DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147) Journal of the National Cancer Institute. ,vol. 106, ,(2014) , 10.1093/JNCI/DJU298
R. Ben Fredj, E. Gross, S. Ben Ahmed, H. Hassine, S. Saguem, The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil Pathologie Biologie. ,vol. 57, pp. 470- 476 ,(2009) , 10.1016/J.PATBIO.2008.05.001